Levalbuterol - XOPENEX nebulized solution | GlobalRPh Renal Dosing Master

READ THE SOURCE-SPECIFIC ANSWER

Renal guidance at a glance

Review first - source-specific qualification

Mixed-formulation RX page excluded from dosing use

The retrieved XOPENEX page describes nebulized solution but includes HFA metered-dose instructions. Its dosing content was not imported.

Before applying: Use the matched nebulized-product label; inspect the separate HFA record for an inhaler.

Evidence for this qualification

Selected-source comparison; independent clinician adjudication pending.

Use the renal measure and units named by this source. Confirm product, indication, age, stable versus changing kidney function, and exact dialysis modality. The selected summary is not a complete prescribing monograph. Renal method and dosing checklist

Choose a source to read (1)

Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.

Official source

XOPENEX nebulized solution: renal caution without a numeric adjustment algorithm

This source only - not a merged recommendation

What matters first

Product: XOPENEX 0.31, 0.63 or 1.25 mg per 3 mL nebulized solution; adult renal summary. Not the HFA metered-dose inhaler.

Renal action / finding: Use caution and careful dose selection; no numeric renal algorithm is supplied.
Evidence or dialysis limit: Supporting renal study used racemic albuterol, not this exact levalbuterol product.
Monitoring / application: Nebulized solution only. The mixed-formulation RX mirror is excluded.

Selected-section summary, not a complete monograph. Independent clinician review remains pending. Read the exact renal measure, dates and full source below.

Product / population: XOPENEX 0.31, 0.63 or 1.25 mg per 3 mL nebulized solution; adult renal summary. Not the HFA metered-dose inhaler.
Renal measure: Renal caution; supporting racemic-albuterol study used CrCl 7-53 mL/min
Source revision: 12/2018
Retrieved: 2026-11-07 (not the revision date)

Qualitative renal precaution. No complete numerical renal schedule is supplied by this selected finding.

Before using this finding

Supporting renal study used racemic albuterol, not this exact levalbuterol product.

Sections 8.6 and 12.3, renal impairment

Renal excretion supports careful dose selection and renal monitoring, particularly in older patients. The supporting study used racemic albuterol in five participants with CrCl 7-53 mL/min and found reduced clearance. High doses of levalbuterol warrant caution in renal impairment. The selected label does not give a numeric renal adjustment or dialysis schedule. This is not an affirmative no-adjustment recommendation and does not authorize HFA inhaler dosing for nebulized solution.

Source revision: 12/2018 | Retrieved: 2026-11-07. Retrieval date is not the revision date.

Source: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7e2644e6-36c5-4988-8e52-bec90e2cd2f0

Scope: Selected named sections summarized; not a complete monograph or independent clinician approval. GlobalRPh v7.4.

Full source card / provenance

All sources, comparison tools and evidence navigation

Source-specific interpretation

What the dialysis evidence actually supports

Removal information alone does not define a maintenance dose, supplemental dose or dialysis schedule. A reported regimen still requires its product, indication, renal measure and dialysis assumptions to match the patient.

XOPENEX nebulized solution: renal caution without a numeric adjustment algorithm

Source retrieved 2026-11-07 - confirm current applicability

No dialysis regimen established in selected content

Read the source and its limits

These manual classifications apply only to the identified selected sections, not every retained source or the entire prescribing information. They are not dosing clearance.

Source-first renal review

Evidence sources and renal implications

Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.

Read 1 source difference / applicability notes

Official product label

XOPENEX nebulized solution: renal caution without a numeric adjustment algorithm

Qualitative renal precaution. No complete numerical renal schedule is supplied by this selected finding.

Before using this finding

Supporting renal study used racemic albuterol, not this exact levalbuterol product.

Dialysis evidence: No dialysis regimen established in selected content

XOPENEX 0.31, 0.63 or 1.25 mg per 3 mL nebulized solution; adult renal summary. Not the HFA metered-dose inhaler.

Renal method: Renal caution; supporting racemic-albuterol study used CrCl 7-53 mL/min
Retrieved: 2026-11-07

Read local renal result Open this source quick answerOpen original reference

Source presence is not independent validation. A label mirror is not a second independent source; review the original reference and exact formulation.

Product / population check

Confirm the exact formulation before using a renal source

These links compare product identities, not interchangeable doses. A selected summary is not a complete prescribing monograph.

Source-specific review points

Mixed-formulation RX page excluded from dosing use

Read the attributed comparison notes and source cards below. No conflict has been silently adjudicated.

Source-quality holds

Find text within this drug

Find a term without leaving this drug

Search the stored clinical text

Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.

Find:

Enter at least two characters. This in-page search is processed in your browser. Do not enter patient identifiers; advertising scripts also run on this page.

All source summaries, original wording and provenance

Before applying a renal protocol

Check the setting. Compare whole sources.

No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.

Share a reproducible source review

Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.

Open / share selected sources

Jump to renal guidance Read 1 difference / caution notes Clinician guide

Only one eligible source version is stored here. No second source is inferred from a reference link. Independent corroboration is still needed.

Build a source-review outline for documentation

This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.

Choose one or two sources above or use the source checkboxes below.

Source-review outline (read-only; copy and complete elsewhere)

Renal-context checklist: population, kidney trend and dialysis

These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.

Population Kidney-function trend Renal replacement setting

Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.

See source-specific renal methods and the clinical interpretation guide for the supporting context.

Read before choosing a regimen

Source differences and product cautions

Search differences across all drugs

These are specific issues found during source review, not an automated judgment that one source is universally correct. A label mirror and its original label are not independent evidence.

Source scope / renal recommendation differences

Mixed-formulation RX page excluded from dosing use

The retrieved XOPENEX page describes nebulized solution but includes HFA metered-dose instructions. Its dosing content was not imported.

How to use this: Use the matched nebulized-product label; inspect the separate HFA record for an inhaler.

XOPENEX nebulized solution: renal caution without a numeric adjustment algorithm Levalbuterol HFA inhaler (XOPENEX HFA)

Selected-source comparison; independent clinician adjudication pending.

Go directly to the relevant source section

Renal dosing and precautions

Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.

Official source

XOPENEX nebulized solution: renal caution without a numeric adjustment algorithm

XOPENEX 0.31, 0.63 or 1.25 mg per 3 mL nebulized solution; adult renal summary. Not the HFA metered-dose inhaler.

Method: Renal caution; supporting racemic-albuterol study used CrCl 7-53 mL/min

Sections 8.6 and 12.3, renal impairment Read this complete source summary

No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.

Compare or copy source versions

All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.

Original content / product scope XOPENEX nebulized solution: renal caution without a numeric adjustment algorithm

Exact product and population matter. This added page contains locally stored, source-specific clinical summaries. Historical handbook information, when present, is identified separately and may conflict with U.S. labeling. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.

Important source distinctions

An RX mirror and its underlying label are not independent clinical confirmations.

Locally stored source content

Exact product and population

Product identity selected for the separately displayed source protocols below. Reference: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7e2644e6-36c5-4988-8e52-bec90e2cd2f0

Product identity and scope

XOPENEX 0.31, 0.63 or 1.25 mg per 3 mL nebulized solution; adult renal summary. Not the HFA metered-dose inhaler.

RDM71-levalbuterol-xopenex-nebulized-scope · Source section: Product identity and scopeRenal section finder

Separate U.S. product-label layer

FDA / DailyMed dosing and renal information

Official Compare this source

XOPENEX nebulized solution: renal caution without a numeric adjustment algorithm

Open original reference

Open / share this exact local source

DailyMed / product prescribing information · XOPENEX 0.31, 0.63 or 1.25 mg per 3 mL nebulized solution; adult renal summary. Not the HFA metered-dose inhaler.

Renal method: Renal caution; supporting racemic-albuterol study used CrCl 7-53 mL/min
Source date: 12/2018
Retrieved: 2026-11-07

Qualitative renal precaution. No complete numerical renal schedule is supplied by this selected finding.

Before using this finding

Supporting renal study used racemic albuterol, not this exact levalbuterol product.

Dialysis evidence: No dialysis regimen established in selected content

Selected named sections summarized; not a complete monograph or independent clinician approval.

Sections 8.6 and 12.3, renal impairment

RDM71-levalbuterol-xopenex-nebulized-label-1 · Source locator: Sections 8.6 and 12.3, renal impairment

Source identity and provenance

Source family: product_label
Source: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7e2644e6-36c5-4988-8e52-bec90e2cd2f0
Retrieved: 2026-11-07
Renal-function method: Renal caution; supporting racemic-albuterol study used CrCl 7-53 mL/min
Source date/version: 12/2018
Hash meaning: Locally authored summary text; not original source HTML, XML or PDF bytes
Local summary SHA-256: e905c97ffb3a436ac250ce66ba34ed2465cdfc79752ca9c5eebf50d48f7a3a33

Provenance and preservation

Additional summaries stored on this page: 1 official-label, 0 RX List, 0 professional, 0 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.

Original source: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7e2644e6-36c5-4988-8e52-bec90e2cd2f0
Source retrieval: 2026-11-07. This is not the source publication or label revision date.
Original source type: multisource addition
Local text SHA-256: fc0f520ac01cfd8ca74e304c55569d7e9c78e20047164e7cdfd4a31fe4f7ebb5
Import versus clinical validation: Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.

This page is an additional exact-product entry, not a recovered GlobalRPh monograph. Its primary scope text and separately attributed clinical summaries are locally included.

Read the full coverage report